Actively Recruiting
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Led by Khyber Medical University Peshawar · Updated on 2025-09-23
25
Participants Needed
2
Research Sites
31 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies. The most common complications are joint bleeds (hemarthroses), which cause chronic changes in joints and ultimately disability. Recurrent hemarthroses often result from chronic synovitis in target joints of patients with hemophilia, a process driven by Vascular Endothelial Growth Factor (VEGF) mediated pathological angiogenesis. Intra-articular administration of Bevacizumab, a VEGF neutralizing monoclonal antibody, may block this process and reduce the frequency of recurrent joint bleeds. This study evaluates the efficacy and safety of intra-articular Bevacizumab for preventing recurrent hemarthrosis in patients with hemophilia and chronic synovitis.
CONDITIONS
Official Title
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of Hemophilia A.
- Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of more than 2 hemarthrosis episodes in the past 6 months.
- Target joint World Federation of Hemophilia (WFH) joint score of 2-3.
- Adequate hematological, renal, and liver function as specified by protocol lab values.
- Ability and willingness to provide informed consent and comply with the study protocol.
You will not qualify if you...
- HIV positive diagnosis.
- Severely damaged joints or anatomical limitations preventing safe injection.
- Contraindications to MRI.
- Uncontrolled hypertension.
- Recent major surgery or trauma within the last 28 days.
- Serious non-healing wound, active cardiovascular disease, or other significant comorbidities that may increase risk or interfere with the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hayatabad Medical Complex
Peshawar, KPK, Pakistan, 25000
Actively Recruiting
2
Institute of Pathology and Diagnostic Medicine (IPDM)
Peshawar, KPK, Pakistan, 25000
Actively Recruiting
Research Team
D
Dr Kinza Ayaz, MBBS
CONTACT
P
Prof. Dr. Yasar M Yousafzai, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here